| Fluvastatin. | |
| | |
MedLine Citation:
|
PMID: 12437496 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Fluvastatin was the first wholly synthetic statin to the market and is effective in reducing total and low density lipoprotein cholesterol, which translates into reductions in coronary heart disease events. The Lescol Intervention Prevention Study has established the effectiveness of the early use of statins in reducing recurrent events in high-risk patients with coronary heart disease post percutaneous coronary interventions. Fluvastatin is well-tolerated with few side effects. The occurrence of significant abnormalities in liver enzymes is infrequent, and the risk of myositis and rhabdomyolysis seems to be less than with other statins. There have been no reports of fatal rhabdomyolysis to date. The potential for drug interactions with fluvastatin is low. It seems safe in combination with cyclosporin and there have been few reports of rhabdomyolysis when using fluvastatin in combination with other lipid-lowering agents. It is nevertheless important to be vigilant for this potentially important side effect and, as with other statins, inform patients of the potential risk and suggestive symptoms. Fluvastatin provides a useful option in treating hypercholesterolaemia in patients at high risk of coronary heart disease. |
| | |
Authors:
|
J M Lawrence; J P D Reckless |
Related Documents
:
|
19784816 - Intensive cholesterol-lowering therapy improves large artery elasticity in acute myocar... 16796076 - Insufficient treatment of hypercholesterolemia among patients hospitalized with chest p... 11759936 - Lipoprotein (a) and lipid levels in young patients with myocardial infarction and their... 9551596 - Lipid-lowering therapy after coronary revascularization: the interventional cardiologis... 23352426 - Contrast volume use in manual vs automated contrast injection systems for diagnostic co... 22902156 - Recent temporal trends and geographic distribution of cardiac procedures in alberta. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 3 ISSN: 1465-6566 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2002 Nov |
Date Detail:
|
Created Date: 2002-11-19 Completed Date: 2003-05-05 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 1631-41 Citation Subset: IM |
Affiliation:
|
Clinical Research Fellow, Diabetes and Lipid Research, Wolfson Centre, Royal United Hospital, Bath, UK. mpsjml@bath.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
adverse effects,
pharmacology*,
therapeutic use* Clinical Trials as Topic Fatty Acids, Monounsaturated / adverse effects, pharmacology*, therapeutic use* Humans Hypercholesterolemia / drug therapy*, economics Indoles / adverse effects, pharmacology*, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Fatty Acids, Monounsaturated; 0/Indoles; 93957-54-1/fluvastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Current oral treatments for erectile dysfunction.
Next Document: Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders.